2020 revenue: $406.6M (–11.6%)
Headquarters: Lewisville, Texas
The musculoskeletal products and therapies company saw revenues return to near-2019 levels by the fourth quarter of 2020. CEO Jon Serbousek said in February that Orthofix plans to capitalize on new capabilities this year.
“A great example is our recent expanded FDA clearance for the Fitbone system, making it the only pediatric lengthening nail in the U.S., and an important addition to our pediatric portfolio,” Serbousek said.
Orthofix in April announced FDA 510(k) clearances for its Construx Mini Ti cervical spacer system and its 3D-printed Forza Ti TLIF spacer system.